LISAPHARMA

Since 1925 Lisapharma is mainly active in the production and development of sterile injectable drugs and it plays an important role in more than 40 countries worldwide. In July 2015 the company has been acquired by ARCADIA SGR and FUTURIMPRESA SGR, two Italian private equity funds. The manufacturing site, based in Erba (Como, Italy), is fully compliant with the GMP requirements both in Italy and in a broad number of international markets where the company generates most of its turnover. The company not only owns a number of Marketing Authorizations in Italy and abroad, for products which are manufactured internally, but its production facility acts as a contract manufacturer for Italian and multinational companies.